WALTHAM, Mass., April 25 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. , a leading manufacturer and marketer of rapid diagnostic products for the consumer and professional markets, today announced that it will release its first quarter 2007 earnings on Wednesday, May 2, 2007. The Company will also host a conference call beginning at 10:00 a.m. (Eastern Time) on that date to discuss these results and other corporate matters. During the conference call the Company may discuss and answer questions concerning business and financial developments and trends. The Company's responses to questions, as well as other matters discussed during the conference call, may contain or constitute information that has not been disclosed previously.
The conference call can be accessed by dialing 973-935-8765 (domestic and international), an access code is not required, or via a link on the Inverness website at http://www.invernessmedical.com/. It is also available via link at http://orion.calleci.com/servlet/estreamgetevent?id=7764&folder=webstream using Real Player or via link at http://orion.calleci.com/servlet/estreamgetevent?id=7763&folder=webstream using Windows Media. A telephone replay of the call will be available by dialing 973-341-3080 (domestic and international) with an access code of 8728492. That replay will be available until 12:00 midnight Eastern on May 5, 2007. An on-demand webcast of the call will be available at the Inverness website (http://www.invernessmedical.com/News.cfm) two hours after the end of the call and will be accessible for 30 days.
For more information about Inverness Medical Innovations, please visit our website at http://www.invernessmedical.com/.
Inverness Medical Innovations is a leading global developer of advanced diagnostic devices and is presently exploring new opportunities for its proprietary electrochemical and other technologies in a variety of professional diagnostic and consumer-oriented applications including immuno- diagnostics with a focus on women's health and cardiology. The Company's new product development efforts, as well as its position as a leading supplier of consumer pregnancy and fertility/ovulation tests and rapid point-of-care diagnostics, are supported by the strength of its intellectual property portfolio. The Company is headquartered in Waltham, Massachusetts.
